Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Set to Pay Quarterly Dividend of $0.47

Key Points

• Thermo Fisher Scientific declared a quarterly dividend of $0.47 per share, payable January 15 to shareholders of record December 15. That amounts to $1.88 annually, a yield of about 0.3%.
• The company has increased its dividend for eight consecutive years. Its 7.6% payout ratio—and projected 6.8% ratio next year—suggests earnings comfortably cover the dividend.
• Thermo Fisher reported quarterly EPS of $6.68, topping the $6.40 analyst estimate, while revenue rose 9.1% year over year to $12.14 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) announced a quarterly dividend on Thursday, November 5th. Investors of record on Tuesday, December 15th will be given a dividend of $0.47 per share by the medical research company on Friday, January 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, December 15th.

Thermo Fisher Scientific has raised its dividend by an average of 0.1% annually over the last three years and has raised its dividend every year for the last 8 years. Thermo Fisher Scientific has a payout ratio of 7.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Thermo Fisher Scientific to earn $27.83 per share next year, which means the company should continue to be able to cover its $1.88 annual dividend with an expected future payout ratio of 6.8%.

Thermo Fisher Scientific Stock Down 4.1%

Thermo Fisher Scientific stock opened at $677.28 on Friday. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $712.17. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The firm has a market cap of $250.94 billion, a PE ratio of 35.72, a P/E/G ratio of 2.88 and a beta of 0.84. The firm's 50 day moving average price is $659.74 and its two-hundred day moving average price is $554.40.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The company had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same quarter last year, the business posted $5.79 EPS. The company's revenue for the quarter was up 9.1% on a year-over-year basis. On average, research analysts predict that Thermo Fisher Scientific will post 25.26 EPS for the current fiscal year.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: The board authorized up to $5 billion in share repurchases, which could support per-share earnings and signal confidence in the company’s prospects. The authorization permits open-market or negotiated purchases but does not require Thermo Fisher to buy shares on a set schedule. Article
• Positive Sentiment: Thermo Fisher introduced value-priced AmpSure qPCR master mixes, positioning the products for labs seeking reliable performance while managing budgets. The launch may support sales, though its near-term financial impact is unclear. Article
• Positive Sentiment: The board declared a quarterly dividend of $0.47 per share, payable January 15, 2027, to shareholders of record December 15. That equals $1.88 annually, or a yield of about 0.3%. Article
• Neutral Sentiment: A market report said TMO shares fell Thursday, although they outperformed the broader market. The report did not identify a specific company-related reason for the decline. Article

About Thermo Fisher Scientific

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research.

The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.